RXST241220P75000
- 0.00
- 0.000.00%
RxSight Newsroom
Insider Sale: Director at $RXST (RXST) Sells 3,782 Shares
3 'Buy' Stocks and 2 'Hold' Stocks According to Oppenheimer
RxSight (RXST) Upgraded to Buy: Here's What You Should Know
Alkermes, DaVita, Jabil, Ralph Lauren, Among Potential M&A Candidates - BofA
Jesse Corley Bought 4.4% More Shares In RxSight
RxSight Insider Bought Shares Worth $1,014,570, According to a Recent SEC Filing
Morgan Stanley Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $70
RxSight, Inc. (RXST) Q3 2024 Earnings Call Transcript Summary
BofA Securities Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $60
Stifel Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $65
Wells Fargo Maintains RxSight(RXST.US) With Buy Rating, Raises Target Price to $56
Express News | Rxsight, Inc. : Wells Fargo Raises Target Price to $56 From $54
BofA Securities Maintains RxSight(RXST.US) With Buy Rating, Cuts Target Price to $60
Needham Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $66
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Artivion (AORT) and RxSight (RXST)
RxSight's Strong Growth and Market Positioning Earns Buy Rating From Analyst
RxSight, Inc. (RXST) Reports Break-Even Earnings for Q3
RxSight Shares Are Trading Lower. The Company Reported Q3 Financial Results.
Express News | Rxsight Inc Q3 Shr View $-0.25 -- LSEG IBES Data
Express News | Rxsight Inc Qtrly Net Loss of $6.3 Mln, or $0.16 per Basic and Diluted Share